These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

328 related articles for article (PubMed ID: 12574910)

  • 1. p53 and mdm-2 expression in Rhabdomyosarcoma of childhood and adolescence: clinicopathologic study by the Kiel Pediatric Tumor Registry and the German Cooperative Soft Tissue Sarcoma Study.
    Leuschner I; Langhans I; Schmitz R; Harms D; Mattke A; Treuner J;
    Pediatr Dev Pathol; 2003; 6(2):128-36. PubMed ID: 12574910
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Orbital rhabdomyosarcoma: relationship between DNA ploidy, p53, bcl-2, MDR-1 and Ki67 (MIB1) expression and clinical behavior.
    Staibano S; Franco R; Tranfa F; Mezza E; Lo Muzio L; Strianese D; Errico ME; Bufo P; Ferrara G; Somma P; Mansueto G; Greco I; Fiorillo A; Bonavolontà G; De Rosa G
    Anticancer Res; 2004; 24(1):249-57. PubMed ID: 15015604
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Altered expression and molecular abnormalities of cell-cycle-regulatory proteins in rhabdomyosarcoma.
    Takahashi Y; Oda Y; Kawaguchi K; Tamiya S; Yamamoto H; Suita S; Tsuneyoshi M
    Mod Pathol; 2004 Jun; 17(6):660-9. PubMed ID: 15098008
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glypican-3 is expressed in rhabdomyosarcomas but not adult spindle cell and pleomorphic sarcomas.
    Thway K; Selfe J; Missiaglia E; Fisher C; Shipley J
    J Clin Pathol; 2011 Jul; 64(7):587-91. PubMed ID: 21493758
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of Wnt/β-catenin signaling in rhabdomyosarcoma.
    Annavarapu SR; Cialfi S; Dominici C; Kokai GK; Uccini S; Ceccarelli S; McDowell HP; Helliwell TR
    Lab Invest; 2013 Oct; 93(10):1090-9. PubMed ID: 23999248
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Amplification of CDK4, MDM2, SAS and GLI genes in leiomyosarcoma, alveolar and embryonal rhabdomyosarcoma.
    Ragazzini P; Gamberi G; Pazzaglia L; Serra M; Magagnoli G; Ponticelli F; Ferrari C; Ghinelli C; Alberghini M; Bertoni F; Picci P; Benassi MS
    Histol Histopathol; 2004 Apr; 19(2):401-11. PubMed ID: 15024701
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MI-63: a novel small-molecule inhibitor targets MDM2 and induces apoptosis in embryonal and alveolar rhabdomyosarcoma cells with wild-type p53.
    Canner JA; Sobo M; Ball S; Hutzen B; DeAngelis S; Willis W; Studebaker AW; Ding K; Wang S; Yang D; Lin J
    Br J Cancer; 2009 Sep; 101(5):774-81. PubMed ID: 19707204
    [TBL] [Abstract][Full Text] [Related]  

  • 8. p53/MDM-2 immunohistochemical expression correlated with proliferative activity in different subtypes of human sarcomas: a ten-year follow-up study.
    Stefanou DG; Nonni AV; Agnantis NJ; Athanassiadou SE; Briassoulis E; Pavlidis N
    Anticancer Res; 1998; 18(6B):4673-81. PubMed ID: 9891539
    [TBL] [Abstract][Full Text] [Related]  

  • 9. (F-18) fluorodeoxyglucose positron emission tomography as a predictor of pathologic grade and other prognostic variables in bone and soft tissue sarcoma.
    Folpe AL; Lyles RH; Sprouse JT; Conrad EU; Eary JF
    Clin Cancer Res; 2000 Apr; 6(4):1279-87. PubMed ID: 10778952
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Integrated genetic and epigenetic analysis defines novel molecular subgroups in rhabdomyosarcoma.
    Seki M; Nishimura R; Yoshida K; Shimamura T; Shiraishi Y; Sato Y; Kato M; Chiba K; Tanaka H; Hoshino N; Nagae G; Shiozawa Y; Okuno Y; Hosoi H; Tanaka Y; Okita H; Miyachi M; Souzaki R; Taguchi T; Koh K; Hanada R; Kato K; Nomura Y; Akiyama M; Oka A; Igarashi T; Miyano S; Aburatani H; Hayashi Y; Ogawa S; Takita J
    Nat Commun; 2015 Jul; 6():7557. PubMed ID: 26138366
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Soft tissue malignancies in childhood and adolescence. Pathology and clinical relevance based on data from the kiel pediatric tumor registry].
    Harms D
    Handchir Mikrochir Plast Chir; 2004 Oct; 36(5):268-74. PubMed ID: 15503256
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cellular expression of adhesion factors in childhood rhabdomyosarcoma.
    Saxon BR; Byard RW; Han P
    Pediatr Pathol Lab Med; 1997; 17(2):259-66. PubMed ID: 9086532
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transition from in situ to invasive testicular germ cell neoplasia is associated with the loss of p21 and gain of mdm-2 expression.
    Datta MW; Macri E; Signoretti S; Renshaw AA; Loda M
    Mod Pathol; 2001 May; 14(5):437-42. PubMed ID: 11353054
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Detection of MDM 2 and p 53 genes in rhabdomyosarcoma by in situ hybridization].
    Lai R; Wang Z; Zhe X
    Zhonghua Bing Li Xue Za Zhi; 1998 Apr; 27(2):127-9. PubMed ID: 11244964
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rhabdomyosarcoma of the urinary bladder and vagina: a clinicopathologic study with emphasis on recurrent disease: a report from the Kiel Pediatric Tumor Registry and the German CWS Study.
    Leuschner I; Harms D; Mattke A; Koscielniak E; Treuner J
    Am J Surg Pathol; 2001 Jul; 25(7):856-64. PubMed ID: 11420456
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activation of the hedgehog pathway confers a poor prognosis in embryonal and fusion gene-negative alveolar rhabdomyosarcoma.
    Zibat A; Missiaglia E; Rosenberger A; Pritchard-Jones K; Shipley J; Hahn H; Fulda S
    Oncogene; 2010 Dec; 29(48):6323-30. PubMed ID: 20818440
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictive value of p53, mdm-2, p21, and mib-1 for chemotherapy response in advanced breast cancer.
    Sjöström J; Blomqvist C; Heikkilä P; Boguslawski KV; Räisänen-Sokolowski A; Bengtsson NO; Mjaaland I; Malmström P; Ostenstadt B; Bergh J; Wist E; Valvere V; Saksela E
    Clin Cancer Res; 2000 Aug; 6(8):3103-10. PubMed ID: 10955790
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic factors in the so-called malignant mesenchymoma: a clinicopathological and immunohistochemical analysis.
    Adachi T; Oda Y; Sakamoto A; Terashi T; Tamiya S; Hachitanda Y; Tsuneyoshi M
    Oncol Rep; 2003; 10(4):803-11. PubMed ID: 12792727
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytodifferentiation and clinical outcome after chemotherapy and radiation therapy for rhabdomyosarcoma (RMS).
    Smith LM; Anderson JR; Coffin CM
    Med Pediatr Oncol; 2002 Jun; 38(6):398-404. PubMed ID: 11984800
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High prognostic significance of Mdm2/p53 co-overexpression in soft tissue sarcomas of the extremities.
    Würl P; Meye A; Schmidt H; Lautenschläger C; Kalthoff H; Rath FW; Taubert H
    Oncogene; 1998 Mar; 16(9):1183-5. PubMed ID: 9528860
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.